generalised anxiety disorder
Mental health · 2007–2014
3decisions
2medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| escitalopram Major depressive disorders, generalised anxiety disorder, and social anxiety disorder. The submission requested listing of a new 20 mg/mL oral liquid strength… | Jul 2014 | Recommended | none received |
| escitalopram oxalate Extension of listing to include moderate to severe generalised anxiety disorder (GAD) as defined by DSM-IV criteria in patients who have not responded to… | Mar 2008 | Recommended with restriction | no section in document |
| escitalopram treatment of social anxiety disorder (social phobia) and generalised anxiety disorder in adults | Mar 2007 | Not recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.